Following on from information provided to NICE by the company in July 2015, the appraisal of Colorectal cancer (metastatic) - MABp1 (after previous treatment) was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
 
Status Discontinued
Technology type Medicine
Decision Selected
Process TA
ID number 917

Email enquiries

External Assessment Group Kleijnen Systematic Reviews Ltd

Stakeholders

Companies sponsors Xbiotech (MABp1)
Others Department of Health
  NHS England
  NHS Hull CCG
  NHS North Kirklees CCG
  Welsh Government
Patient carer groups Beating Bowel Cancer
  Bowel Cancer Information
  Bowel Cancer UK
  Cancer Black Care
  Cancer Equality
  Colostomy Association
  HAWC
  Helen Rollason Cancer Charity
  Independent Cancer Patients Voice
  IA: lleostomy and Internal Pouch Support Group
  Macmillan Cancer Support
  Maggie’s Centres
  Marie Curie Cancer Care
  Muslim Council of Britain
  South Asian Health Foundation
  Specialised Healthcare Alliance
  Tenovus Cancer Care
Professional groups Association of Anaesthetists
  Association of Cancer Physicians
  Association of Coloproctology of Great Britain and Ireland
  Association of Surgeons of Great Britain and Ireland
  BASO – The Association for Cancer Surgery
  British Geriatrics Society
  British Institute for Radiology
  British Psychosocial Oncology Society
  British Society of Gastroenterology
  Cancer Research UK
  Pelican Cancer Foundation
  Royal College of Anaesthetists
  Royal College of General Practitioners
  Royal College of Nursing
  Royal College of Pathologists
  Royal College of Physicians
  Royal College of Radiologists
  Royal College of Surgeons
  Royal Pharmaceutical Society
  Royal Society of Medicine
  Society and College of Radiographers
  UK Clinical Pharmacy Association
  UK Oncology Nursing Society
  UK Health Forum
Associated public health groups Public Health England
  Public Health Wales
General commentators Allied Health Professionals Federation
  Board of Community Health Councils in Wales
  British National Formulary
  Care Quality Commission
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Medicines and Healthcare products Regulatory Agency
  National Association of Primary Care
  National Pharmacy Association
  NHS Alliance
  NHS Commercial Medicines Unit
  NHS Confederation
  Scottish Medicines Consortium
Relevant research groups Bowel & Cancer Research
  Clinical Research Trials Unit
  Cochrane Colorectal Cancer Group
  CORE (Digestive Disorders Foundation)
  Institute of Cancer Research
  MRC Clinical Trials Unit
  National Cancer Research Institute
  National Cancer Research Network
  National Institute for Health Research

Timeline

Key events during the development of the guidance:

Date Update
16 November 2022 Discontinued. Following on from information provided to NICE by the company in July 2015, the appraisal of Colorectal cancer (metastatic) - MABp1 (after previous treatment) was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
27 March 2018 Suspended. The EMA’s Committee for Medicinal Products for Human Use (CHMP) has adopted a negative opinion recommending the refusal of the marketing authorisation for this drug in this indication. This appraisal will therefore remain suspended.
07 November 2016 Suspended, The company have not made a submission to NICE. We are discussing the next steps with the company.
20 May 2016 Draft scope documents
13 May 2016 Referral
05 April 2016 Invitation to participate

For further information on our processes and methods, please see our CHTE processes and methods manual